Underlying NPATA nearly doubled year-over-year, with revenue up 28% and strong margin expansion. Patient and clinician growth accelerated, and a fully imputed interim dividend was declared, reflecting robust performance.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.